Spruce Biosciences Inc. (SPRB): Price and Financial Metrics

Spruce Biosciences Inc. (SPRB): $2.95

0.23 (+8.46%)

POWR Rating

Component Grades













Add SPRB to Watchlist
Sign Up

Industry: Biotech



in industry

SPRB Stock Price Chart Interactive Chart >

Price chart for SPRB

SPRB Price/Volume Stats

Current price $2.95 52-week high $3.38
Prev. close $2.72 52-week low $0.95
Day low $2.72 Volume 104,461
Day high $3.09 Avg. volume 4,340,723
50-day MA $1.63 Dividend yield N/A
200-day MA $1.63 Market Cap 69.50M

Spruce Biosciences Inc. (SPRB) Company Bio

Spruce Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on developing novel therapies for rare diseases affecting the endocrine system. The company was founded in 2014 and is headquartered in Daly City, CA.

SPRB Latest News Stream

Event/Time News Detail
Loading, please wait...

SPRB Latest Social Stream

Loading social stream, please wait...

View Full SPRB Social Stream

Latest SPRB News From Around the Web

Below are the latest news stories about SPRUCE BIOSCIENCES INC that investors may wish to consider to help them evaluate SPRB as an investment opportunity.

Spruce Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

SOUTH SAN FRANCISCO, Calif., January 09, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today provided an update on its clinical programs, anticipated upcoming milestones and strategic priorities for advancing tildacerfont in classic congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS).

Yahoo | January 9, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

The final day of trading this week is here and we're starting it off with a look at the biggest pre-market stock movers for Friday!

William White on InvestorPlace | January 6, 2023

Spruce Biosciences (NASDAQ: SPRB) Enters Into Collaboration with Kaken Pharmaceutical to Develop Tildacerfont for CAH in Japan

Spruce Biosciences, Inc. (NASDAQ: SPRB) is engaged as a late-stage biopharmaceutical company, which is focused on the research, development and

Barchart | January 6, 2023

Spruce Biosciences Surges On Tie-up With Kaken Pharma To Develop Investigational Drug Tildacerfont

Shares of Spruce Biosciences, Inc. (SPRB) are rising more than 100% Friday morning after the company announced partnership with Japan''s Kaken Pharmaceutical to develop Spruce''s investigational drug, tildacerfont, for the treatment of congenial adrenal hyperplasia (CAH).

RTT News | January 6, 2023

Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday''s Mid-Day Session

Gainers Swvl Holdings Corp. (NASDAQ: SWVL ) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process. Spruce Biosciences, Inc. (NASDAQ: SPRB ) shares jumped 100.8% to $2.51. Spruce Biosciences and Kaken Pharmaceutical reported an exclusive licensing agreement to develop and commercialize Tildacerfont for CAH in Japan. MedAvail Holdings, Inc. (NASDAQ: MDVL ) gained 54% to $0.4745. MedAvail Holdings, during November, posted a Q3 loss of $0.15 per share. CytomX Therapeutics, Inc. (NASDAQ: CTMX ) climbed 46.4% to $2.6198. CytomX and Moderna reported a strategic research collaboration for mRNA-based conditionally activated therapeutics. Zomedica Corp. (NYSE: ZOM ) gained 38% to $0.2649 after Dawson James initiated coverage on the stock with a Buy rating ...

Benzinga | January 6, 2023

Read More 'SPRB' Stories Here

SPRB Price Returns

1-mo 168.82%
3-mo 173.15%
6-mo 43.90%
1-year 16.14%
3-year N/A
5-year N/A
YTD 168.82%
2022 -75.39%
2021 -81.65%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7824 seconds.